Nuvilex Cites Study that Suggests Red Yeast Rice, an Active Ingredient in Cinnechol, Can Help to Improve Cardiovascular Health
Study Published in Annals of Internal Medicine
A recent study titled “Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial,” led by cardiologists Dr.
“Many synthetic statins have been derived from red yeast rice and other naturally occurring phytochemicals,” stated
Cinnechol, which contains red yeast rice extract as well as a blend of other ingredients known to improve cardiovascular function (including niacin and guggul gum extract), may provide a natural alternative for those who have high cholesterol and are intolerant of, or elect not to take, statin drugs. Cinnechol can be purchased online by visiting www.cinnechol.com.
“Red yeast rice has now been more thoroughly researched and recognized as an important tool for safely normalizing blood lipids, especially LDL cholesterol,” reported Cinnechol co-inventor
Cinnechol, an ingestible capsule made of all-natural ingredients, is manufactured and sold by Cinnechol, Inc. (a wholly owned subsidiary of Nuvilex, Inc.). Cinnechol is designed to help maintain normal cholesterol levels and to support normal cardiovascular function. Cinnechol, along with a healthy diet and exercise regimen, is intended to serve as a dietary supplement to help individuals manage numerous cardiovascular and metabolic disorders (including dyslipidemia, hypertension, hypoglycemia, and hyperglycemia).
About Nuvilex, Inc.
Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company’s focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as “intends”, “anticipates”, “believes”, “expects”, and “hopes” and involve a number of risks and uncertainties that could cause the Company’s actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Investor Relations Contacts: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: firstname.lastname@example.org Amy Glynn/Ashleigh Barreto The Ruth Group Ph: 646-536-7023/7028 Email: email@example.com Email: firstname.lastname@example.org Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: email@example.com
SOURCE Nuvilex, Inc.